Merck (MRK) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Merck (MRK) do?
Merck & Co Inc (MRK) is a U.S.-listed company in Healthcare (Drug Manufacturers - General). What it does: Sells prescription oncology drugs, human vaccines, hospital acute care therapies, and livestock medications worldwide. Manufactures prescription medicines, vaccines, and animal health products, relying heavily on a blockbuster oncology. It is worth $327.41B on the market and sold $67.23B over the last year.
- Market cap
- $327.41B
- P/E ratio
- 135.6×
- Annual sales
- $67.23B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Brief updated
- Nov 07, 2026
Brands and businesses behind MRK
- Keytruda: Immunotherapy drug treating various cancers, sold globally to hospitals and cancer clinics.
- Gardasil: Vaccine protecting against human papillomavirus, sold to healthcare providers, public clinics, and governments.
- Januvia: Oral medication for type 2 diabetes, generating revenue via retail pharmacies and prescription drug plans.
- Bridion: Reversal medication for anesthesia muscle relaxants, generating sales from hospital surgical departments worldwide.
- Bravecto: Veterinary medication protecting companion animals from fleas and ticks, sold through veterinary clinics and distributors.
MRK’s flags, in plain English
Each flag is a number from Merck’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 07, 2026.
Wide Gross Margin
Gross margin of 69.7% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Still Climbing
Sales up 9.3% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Pays You to Hold
Pays a 2.56% dividend a year. The company pays part of its profit to shareholders in cash. A dividend can be cut, so it is not guaranteed.
Debt Is Driving
Heavy debt, 120% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
1 more risk note open with the free trial. Try it free for 7 days.
Questions about MRK
How big is Merck?
Merck’s market cap is $327.41B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $67.23B: what customers paid the company over the last year, before any costs.
What is MRK’s P/E ratio?
MRK’s P/E ratio is 135.6×. Investors pay about 135.6 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with MRK?
Keytruda accounts for nearly half of company revenue, creating high vulnerability to its upcoming patent expiration. That is one risk on Merck’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Merck’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. MRK’s filings on SEC.gov. The Margin Monkey is research, not advice.
